Issue Date: June 19, 2017 | Web Date: June 14, 2017
FDA takes aim at opioid epidemic
The U.S. Food & Drug Administration has requested that Endo Pharmaceuticals remove its painkiller Opana ER from the market. Opana ER’s active ingredient, oxymorphone, is an opioid similar to morphine but with an added hydroxyl group that makes it 10 times as potent. The agency says this is the first time it has taken steps to halt sales of an opioid over concerns of public abuse. . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society